Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPC-Encapsulated NGF in ALS
NCT06391645Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of Nerve growth factor in amyotrophic lateral sclerosis (ALS), sponsored by Beijing Tiantan Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
Nerve growth factor
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06391645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391645.